Abstract：
The objective of this systematic review was to establish an overview of aromatase inhibitor-related symptoms reported by postmenopausal women with nonmetastatic, estrogen receptor-positive breast cancer.
Eight databases (PubMed, Cochrane, Cumulative Index to Nursing and Allied Health Literature [CINAHL], Ovid EMBASE, Ovid MEDLINE, PsycINFO, Scopus, and Web of Science) were searched for trials published between January 2004 and November 2021. Inclusion criteria were studies exploring patient-reported aromatase inhibitor-related symptoms in postmenopausal women with nonmetastatic estrogen receptor-positive breast cancer. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and the Mixed Method Appraisal Tool were used to rate the quality of the trials included. Of 325 full-text papers, 10 were included. Patient-reported symptoms were clustered by using the European Organization for Research and Treatment of Cancer Quality of Life C30 questionnaire domains. Additional domains were used to cluster other symptoms mentioned: menopausal, sex-related, body alteration, and eye-related. The following clusters were the most frequently presented: sex-related (14 symptoms), pain (9 symptoms), insomnia (5 symptoms), and menopausal (5 symptoms).
The target group reported a variety of symptoms related to aromatase inhibitors. No tools are currently available to measure all the symptoms reported, indicating a need to revise the tools to acknowledge additional symptoms. Prospective studies are needed to investigate the prevalence of aromatase inhibitor-related symptoms in women with breast cancer.
Identification of patient-reported clinically relevant symptoms can enable targeted symptom assessment and management strategies for women with breast cancer undergoing aromatase inhibitor treatment.
Eight databases (PubMed, Cochrane, Cumulative Index to Nursing and Allied Health Literature [CINAHL], Ovid EMBASE, Ovid MEDLINE, PsycINFO, Scopus, and Web of Science) were searched for trials published between January 2004 and November 2021. Inclusion criteria were studies exploring patient-reported aromatase inhibitor-related symptoms in postmenopausal women with nonmetastatic estrogen receptor-positive breast cancer. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and the Mixed Method Appraisal Tool were used to rate the quality of the trials included. Of 325 full-text papers, 10 were included. Patient-reported symptoms were clustered by using the European Organization for Research and Treatment of Cancer Quality of Life C30 questionnaire domains. Additional domains were used to cluster other symptoms mentioned: menopausal, sex-related, body alteration, and eye-related. The following clusters were the most frequently presented: sex-related (14 symptoms), pain (9 symptoms), insomnia (5 symptoms), and menopausal (5 symptoms).
The target group reported a variety of symptoms related to aromatase inhibitors. No tools are currently available to measure all the symptoms reported, indicating a need to revise the tools to acknowledge additional symptoms. Prospective studies are needed to investigate the prevalence of aromatase inhibitor-related symptoms in women with breast cancer.
Identification of patient-reported clinically relevant symptoms can enable targeted symptom assessment and management strategies for women with breast cancer undergoing aromatase inhibitor treatment.
摘要：
目的：本系统评价的目的是概述绝经后非转移性妇女报告的芳香化酶抑制剂相关症状，雌激素受体阳性乳腺癌.
方法：八个数据库(PubMed，科克伦,护理和相关健康文献累积指数[CINAHL]，OvidEmbase,OvidMEDLINE,PsycINFO,Scopus,和WebofScience）搜索了2004年1月至2021年11月之间发表的试验。纳入标准是探索绝经后女性非转移性雌激素受体阳性乳腺癌患者报告的芳香化酶抑制剂相关症状的研究。使用系统评价和荟萃分析指南的首选报告项目和混合方法评估工具对纳入的试验质量进行评级。在325篇全文论文中，包括10个。通过使用欧洲癌症生活质量研究和治疗组织C30问卷域对患者报告的症状进行聚类。其他领域被用来聚集提到的其他症状：更年期，性相关,身体改变,和眼睛有关。以下集群是最常见的：性别相关(14种症状)，疼痛（9种症状）失眠（5种症状）和更年期（5症状）。
结论：目标组报告了与芳香化酶抑制剂相关的多种症状。目前没有工具可用于测量报告的所有症状，表明需要修改工具以确认其他症状。需要进行前瞻性研究以调查乳腺癌女性中芳香化酶抑制剂相关症状的患病率。
结论：识别患者报告的临床相关症状可以为接受芳香化酶抑制剂治疗的乳腺癌女性提供有针对性的症状评估和管理策略。
方法：八个数据库(PubMed，科克伦,护理和相关健康文献累积指数[CINAHL]，OvidEmbase,OvidMEDLINE,PsycINFO,Scopus,和WebofScience）搜索了2004年1月至2021年11月之间发表的试验。纳入标准是探索绝经后女性非转移性雌激素受体阳性乳腺癌患者报告的芳香化酶抑制剂相关症状的研究。使用系统评价和荟萃分析指南的首选报告项目和混合方法评估工具对纳入的试验质量进行评级。在325篇全文论文中，包括10个。通过使用欧洲癌症生活质量研究和治疗组织C30问卷域对患者报告的症状进行聚类。其他领域被用来聚集提到的其他症状：更年期，性相关,身体改变,和眼睛有关。以下集群是最常见的：性别相关(14种症状)，疼痛（9种症状）失眠（5种症状）和更年期（5症状）。
结论：目标组报告了与芳香化酶抑制剂相关的多种症状。目前没有工具可用于测量报告的所有症状，表明需要修改工具以确认其他症状。需要进行前瞻性研究以调查乳腺癌女性中芳香化酶抑制剂相关症状的患病率。
结论：识别患者报告的临床相关症状可以为接受芳香化酶抑制剂治疗的乳腺癌女性提供有针对性的症状评估和管理策略。
